New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to ...
As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug ...
Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even ...
Leerink notes that Amgen’s Phase 2 MariTide showed “up to ~20% average weight loss at 52 weeks” in nondiabetic obese/overweight patients, which is roughly on par with the hi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback